Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Suzuken Co's Debt-to-EBITDA or its related term are showing as below:
TSE:9987's Debt-to-EBITDA is not ranked *
in the Medical Distribution industry.
Industry Median: 2.29 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Suzuken Co Debt-to-EBITDA Related Terms
Suzuken Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Suzuken Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:9987 vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Suzuken Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzuken Co Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Suzuken Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Suzuken Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Suzuken Co (TSE:9987) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Suzuken Co. According to the industry distribution chart, Suzuken Co ranks #999999 out of 91 companies in the Medical Distribution industry.
Is Suzuken Co's Debt-to-EBITDA too high?
Suzuken Co's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Suzuken Co ranks #999999 out of 91 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Suzuken Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzuken Co's Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Suzuken Co ranks #999999 out of 91 companies for Debt-to-EBITDA. This places Suzuken Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.29, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Suzuken Co. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzuken Co's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzuken Co stock overvalued right now?
Based on GuruFocus' analysis, Suzuken Co (TSE:9987) is currently considered Modestly Undervalued. The stock's GF Value™ is 円5,931.03, compared to a current price of 円5,000.00 — trading 15.7% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Suzuken Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Suzuken Co (TSE:9987), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzuken Co (TSE:9987) Overvalued in 2026?
Based on GuruFocus' analysis, Suzuken Co stock appears to be undervalued.
The current stock price of 円5,000.00 is trading 15.7% below its estimated GF Value™ of 円5,931.03.
GuruFocus considers Suzuken Co to be Modestly Undervalued.
Key valuation signals for TSE:9987:
Debt-to-EBITDA: 0.00
GF Value™: 円5,931.03 vs. price of 円5,000.00 (15.7% below fair value)
No single metric tells the full story. See the TSE:9987 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzuken Co Ltd is engaged in the manufacture and sale of pharmaceuticals and medical devices, and in providing insurance, pharmacy, and nursing care services. The company operates through segments, including Pharmaceutical Wholesale business, Healthcare product development business, Specialty Pharmaceuticals Distribution business, Regional medical nursing care support business, and Medical-related Services business. It generates the majority of its revenue from the Pharmaceutical Wholesale Business segment, which sells prescription pharmaceuticals, diagnostic reagents, medical equipment, and medical supplies.
79GF Score
Get the complete analysis for TSE:9987
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9987 has been successfully added to your 
